These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17971711)

  • 21. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
    Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
    J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
    Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
    Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
    Edén A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
    J Infect Dis; 2007 Dec; 196(12):1779-83. PubMed ID: 18190258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
    J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.
    Premeaux TA; D'Antoni ML; Abdel-Mohsen M; Pillai SK; Kallianpur KJ; Nakamoto BK; Agsalda-Garcia M; Shiramizu B; Shikuma CM; Gisslén M; Price RW; Valcour V; Ndhlovu LC
    J Neurovirol; 2019 Apr; 25(2):150-161. PubMed ID: 30478799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
    Delille CA; Pruett ST; Marconi VC; Lennox JL; Armstrong WS; Arrendale RF; Sheth AN; Easley KA; Acosta EP; Vunnava A; Ofotokun I
    J Clin Pharmacol; 2014 Sep; 54(9):1063-71. PubMed ID: 24691856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
    Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
    Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
    Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
    J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
    Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
    J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma.
    Hellmuth J; Slike BM; Sacdalan C; Best J; Kroon E; Phanuphak N; Fletcher JLK; Prueksakaew P; Jagodzinski LL; Valcour V; Robb M; Ananworanich J; Allen IE; Krebs SJ; Spudich S
    J Infect Dis; 2019 Nov; 220(12):1885-1891. PubMed ID: 30668739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
    Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
    Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine.
    Gisslén M; Norkrans G; Svennerholm B; Hagberg L
    J Infect Dis; 1997 Feb; 175(2):434-7. PubMed ID: 9203666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
    Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
    Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.